Phase 2 trial of temozolomide using protracted low‐dose and whole‐brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases

Abstract

The concomitant use of WBRT and protracted low-dose TMZ appears to be an active, well-tolerated regimen. The observed antitumor activity suggests the need for further investigation of this schedule in combination with other anticancer agents for the concomitant treatment of brain metastases and primary cancers.